RxDoctor Payments Data

Dagoberto de la Vega, MD

Internal Medicine · Miami, FLNPI 1114979671

Payments from drug & device makers

$2,386,087in general payments, 2019–2025

Across 110 payments — averaging $21,692 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$2.3M
  • AbbVie$42K
  • Melinta Therapeutics, LLC$2K

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer94$2,341,897
AbbVie15$41,790
Melinta Therapeutics, LLC1$2,400

How this compares

$2,386,087 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$262,272
Medicare patients
275
Services billed
3,056

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban513$338,565
JanuviaSitagliptin Phosphate151$106,336
XareltoRivaroxaban140$101,434
MounjaroTirzepatide83$87,567
OzempicSemaglutide72$79,880
FarxigaDapagliflozin Propanediol106$68,542
EntrestoSacubitril/Valsartan78$59,312
LinzessLinaclotide104$58,116
TradjentaLinagliptin76$47,624
RestasisCyclosporine68$42,010
JardianceEmpagliflozin63$41,866
TrulicityDulaglutide41$39,373
XifaxanRifaximin11$37,595
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$33,284
MyrbetriqMirabegron55$27,499

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$2,341,897$338,565513 claims
AbbVieLinzess, Restasis$41,790$100,126172 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →